08/20/2026
Could a personalized vaccine help the immune system fight cancer?
New Phase 3 results in patients with high-risk melanoma that had been completely removed by surgery are very encouraging.
Researchers created an individualized mRNA-based cancer vaccine using information from each patient’s own tumor and combined it with Keytruda (pembrolizumab).
An easy way to understand the idea:
🎯 Personalized vaccine: helps train the immune system to recognize features of that patient’s cancer.
🛑 Keytruda: removes an important immune “brake,” helping immune cells recognize and attack cancer cells.
In the Phase 3 study, the combination performed better than Keytruda alone in delaying the return of melanoma and distant spread of melanoma.
But this distinction is important:
This is promising Phase 3 evidence, and the detailed results still need to be presented. The personalized vaccine is investigational and is not yet a new FDA-approved standard treatment.
Cancer treatment is becoming increasingly personalized—not simply based on where a cancer started, but also on the biology of an individual patient’s tumor.
— Dr. Elham Abbasi
Medical Oncologist
For general education only. This information is not a substitute for individualized medical advice.